400 Participants Needed

Automated Smoking Cessation Outreach for Cancer Patients

EY
Overseen ByEdgar Yu
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of California, San Francisco
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a multi-arm, randomized controlled, pilot study which will recruit cancer patients who have been seen by a UCSF Cancer Center-affiliated clinical department to evaluate the efficacy of "CareConnect". This is the first study to assess the efficacy CareConnect, a combination of the Ask-Advise-Connect (AAC) with an Interactive Voice Response (IVR) delivering cancer-targeted educational messages to support referral to smoking cessation resources for patients with cancer.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications.

Is the Automated Smoking Cessation Outreach for Cancer Patients generally safe for humans?

The studies reviewed focus on the implementation and effectiveness of smoking cessation programs, but they do not report any specific safety concerns related to the interventions, suggesting that these programs are generally considered safe for human participants.12345

How is the CareConnect treatment different from other smoking cessation treatments for cancer patients?

CareConnect is unique because it uses an automated system to connect cancer patients with smoking cessation support through their electronic health records, making it easier for healthcare providers to identify smokers and refer them to treatment. This approach streamlines the process and increases the likelihood of patients engaging in smoking cessation programs, which is often a challenge in traditional settings.12467

What data supports the effectiveness of the treatment AutoReach, CareConnect, Ask-Advise-Connect (AAC) with Interactive Voice Response (IVR) for smoking cessation in cancer patients?

The Ask-Advise-Connect (AAC) approach has shown effectiveness in linking smokers to Quitline services, with 94.8% of those contacted enrolling in treatment, indicating its potential to engage patients in smoking cessation. Additionally, using electronic health records to identify and refer smokers to treatment programs has been shown to improve engagement rates, suggesting that these methods can effectively support smoking cessation efforts in cancer patients.12368

Who Is on the Research Team?

JT

Janice Tsoh, PhD

Principal Investigator

University of California, San Francisco

Are You a Good Fit for This Trial?

This trial is for adult cancer patients who smoke or use tobacco, including e-cigarettes. Participants must understand English, Spanish, Cantonese, or Mandarin and be willing to sign a consent form. They should have visited a UCSF Cancer Center-affiliated department recently.

Inclusion Criteria

Self-reported current use of tobacco, including e-cigarette on EHR
I understand and can follow the study's procedures.
I have been diagnosed with cancer.
See 2 more

Exclusion Criteria

Contraindication to any study-related procedure or assessment
No valid contact telephone number
Currently hospitalized or having been discharged from inpatient setting within the past month (according to EHR)

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Enrollment and Baseline Assessment

Participants are enrolled and complete a baseline assessment. They receive automated calls/SMS texts for tobacco cessation intervention.

1 week
1 call (automated), 1 SMS (automated)

Intervention

Participants receive CareConnect or AutoReach calls/SMS texts, including assessments, motivational enhancement, and referral options for tobacco cessation.

3 months
Up to 2 calls (automated), 1 SMS (automated) per contact attempt

Follow-up

Participants are monitored for acceptance of referrals and satisfaction with the intervention. A 3-month survey is conducted.

3 months
1 survey (online, telephone, or postal mail)

In-depth Interviews (Optional)

Selected participants undergo in-depth semi-structured qualitative interviews.

1 month

What Are the Treatments Tested in This Trial?

Interventions

  • AutoReach
  • Biospecimen samples
  • CareConnect
Trial Overview The study tests 'CareConnect', which combines advice on quitting smoking with automated phone messages tailored for cancer patients. It aims to see if this helps more people quit smoking compared to usual care methods.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: CareConnect (Intervention)Experimental Treatment2 Interventions
Group II: AutoReach (Control)Experimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, San Francisco

Lead Sponsor

Trials
2,636
Recruited
19,080,000+

Tobacco Related Disease Research Program

Collaborator

Trials
27
Recruited
26,300+

Published Research Related to This Trial

A novel automated Patient Reported Outcomes (PRO) tobacco use screener was implemented in the electronic health record system, allowing 4589 cancer patients to be screened, with 3.6% identified as recent smokers.
Of those who screened positive, nearly 50% engaged in smoking cessation treatment, suggesting that this system may enhance the identification of smokers and improve treatment engagement compared to traditional methods in oncology settings.
Leveraging Patient Reported Outcomes Measurement via the Electronic Health Record to Connect Patients with Cancer to Smoking Cessation Treatment.May, JR., Klass, E., Davis, K., et al.[2020]
The Ask-Advise-Connect (AAC) approach effectively linked 12% of current smokers at a Federally Qualified Health Center to Quitline services, demonstrating its potential to enhance smoking cessation efforts in low-socioeconomic status communities.
Post-implementation feedback from clinic staff indicated that AAC was easy to implement and positively impacted patient care, suggesting it could become a standard practice for smoking cessation in similar healthcare settings.
The implementation of ask-advise-connect in a federally qualified health center: a mixed methods evaluation using the re-aim framework.Shorey Fennell, B., Cottrell-Daniels, C., Hoover, DS., et al.[2023]
Approximately 45% of cancer patients had missing tobacco use history in their electronic medical records, highlighting a significant gap in screening that could affect treatment outcomes.
Stakeholders expressed a strong interest in improving tobacco screening and cessation services, but identified barriers such as cultural differences, time constraints, and lack of training, indicating a need for tailored interventions to enhance tobacco cessation efforts among diverse patient populations.
Implementation planning for equitable tobacco treatment services: a mixed methods assessment of contextual facilitators and barriers in a large comprehensive cancer center.Tsui, J., Sloan, K., Sheth, R., et al.[2023]

Citations

Leveraging Patient Reported Outcomes Measurement via the Electronic Health Record to Connect Patients with Cancer to Smoking Cessation Treatment. [2020]
The implementation of ask-advise-connect in a federally qualified health center: a mixed methods evaluation using the re-aim framework. [2023]
Implementation planning for equitable tobacco treatment services: a mixed methods assessment of contextual facilitators and barriers in a large comprehensive cancer center. [2023]
Increased Reach and Effectiveness With a Low-Burden Point-of-Care Tobacco Treatment Program in Cancer Clinics. [2023]
A randomised controlled trial to prevent smoking relapse among recently quit smokers enrolled in employer and health plan sponsored quitlines. [2019]
Effectiveness of a chat-bot for the adult population to quit smoking: protocol of a pragmatic clinical trial in primary care (Dejal@). [2020]
Feasibility of Patient Navigation-Based Smoking Cessation Program in Cancer Patients. [2022]
Development of a Conversational Agent for Individuals Ambivalent About Quitting Smoking: Protocol for a Proof-of-Concept Study. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security